Abstract
The primary molecular endpoint for many DMD clinical trials and the proof of concept for therapeutic approaches is the induction or increase in the production of de novo dystrophin. However, it is important to not only quantify levels of restored dystrophin following treatment, but to determine its molecular functionality using unbiased methodologies. We assessed if induced dystrophin following 48 weeks treatment with an exon 53 skipping morpholino (golodirsen), which we previously demonstrated to be capable of inducing dystrophin restoration, also results in enhanced levels of dystrophin associated proteins (DAPs) and a reduction in regenerating myofibres in post treatment biopsies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.